Antiviral Therapeutics Market by Drug, Therapy, Distribution

Description

List of Tables

[199 Pages Report] The Antiviral Therapeutics Market size was estimated at USD 69.54 billion in 2022 and expected to reach USD 75.53 billion in 2023, at a CAGR 8.32% to reach USD 131.82 billion by 2030.

Global Antiviral Therapeutics Market

KEY MARKET STATISTICS
Base Year [2022]	USD 69.54 billion
Estimated Year [2023]	USD 75.53 billion
Forecast Year [2030]	USD 131.82 billion
CAGR (%)	8.32%

Antiviral therapeutics are therapeutics specifically designed to target viral pathogens and inhibit their replication, thereby alleviating the symptoms and spread of viral diseases. Antiviral drugs are used in various healthcare settings, ranging from hospitals to specialty clinics and home care. They are prescribed for the treatment of diverse viral infections, including influenza, hepatitis, Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), and the recent SARS-CoV-2. The rising prevalence of various chronic and viral diseases worldwide is expanding the need for antiviral therapeutics. Growing pharmaceutical research and development activities with increasing healthcare expenditure are driving the growth of the antiviral therapeutics market. Side effects associated with antiviral drugs high cost of development of medication hampers the growth of antiviral therapeutics. Growing research and development activities to develop antiviral therapeutics by market vendors are expected to create opportunities for market growth.

Regional Insights

In the Americas, the antiviral therapeutics market is highly developing due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of viral infections. Innovative treatment regimens and a strong focus on research & development (R&D) have been catalyzed by significant investment from both the public and private sectors. European Union (EU) countries collectively represent a significant market, with overarching regulations governed by the European Medicines Agency (EMA). High standards of healthcare and a relatively wealthy population translate to a strong consumer need for the latest therapeutic options. The prevalence of universal health coverage across many EU countries means that purchasing behavior is largely determined by regulatory endorsements and national health care policies. The Middle East and Africa (MEA) presents a diverse market with varying degrees of access to healthcare. Wealthier nations in the Middle East have the financial resources to invest in modern therapeutics, while many African countries face significant barriers to access. Asia-Pacific region is rapidly expanding its presence in the antiviral therapeutics market, marked by increasing investment in pharmaceutical R&D and a large population base requiring medical treatment. The growing availability of local manufacturing and government initiatives in the region to improve healthcare access is driving market growth in Asia-Pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antiviral Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antiviral Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Limited, AstraZeneca PLC, Atea Pharmaceuticals, Inc., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Ltd., Cocrystal Pharma, Inc., Daiichi Sankyo Company, Ltd., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Labs Limited, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Syngene International Limited, Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., Venatorx Pharmaceuticals, Inc., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Antiviral Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug
- Hepatitis Antiviral Drug
- Herpes Antiviral Drug
- HIV Antiviral Drug
- Influenza Antiviral Drug
Therapy
- DNA Polymerase Inhibitors
  - Non-nucleosides
  - Purine Nucleoside Analogues
  - Pyrimidine Nucleoside Analogues
- Neuraminidase Inhibitors
- Protease Inhibitors
- Reverse Transcriptase Inhibitors
  - Nonnucleoside RTIs
  - Nucleoside RTIs
  - Nucleotide RTIs
Distribution
- Hospital Pharmacy
- Independent Pharmacy & Drug Store
- Online Pharmacy
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antiviral Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antiviral Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Antiviral Therapeutics Market?

4. What is the market share of the leading vendors in the Antiviral Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Antiviral Therapeutics Market?

Product Code: MRR-037F3DB2592C

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Antiviral Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising Prevalence of Viral Diseases Including HIV and Hepatitis
  - 5.1.1.2. Application of Antiviral Therapeutics in Pediatric Care and Respiratory Diseases
  - 5.1.1.3. Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
- 5.1.2. Restraints
  - 5.1.2.1. Relatively High Cost Associated with Antiviral Drug Treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in Molecular Biology Promoting Drug Development
  - 5.1.3.2. Improved Testing and Analysis of Viral Infections
- 5.1.4. Challenges
  - 5.1.4.1. Adverse Effects of Antiviral Drugs
5.2. Market Segmentation Analysis
- 5.2.1. Drug: Growing usage of influenza antiviral drugs are used to treat and prevent influenza.
- 5.2.2. Therapy: Rising inclination towards DNA polymerase inhibitors for the management of HSV and VZV
- 5.2.3. Distribution: Growing adoption of online pharmacy with the rising digital transformation initiatives
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter's Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization

6. Antiviral Therapeutics Market, by Drug

6.1. Introduction
6.2. Hepatitis Antiviral Drug
6.3. Herpes Antiviral Drug
6.4. HIV Antiviral Drug
6.5. Influenza Antiviral Drug

7. Antiviral Therapeutics Market, by Therapy

7.1. Introduction
7.2. DNA Polymerase Inhibitors
- 7.3.1. Non-nucleosides
- 7.3.2. Purine Nucleoside Analogues
- 7.3.3. Pyrimidine Nucleoside Analogues
7.3. Neuraminidase Inhibitors
7.4. Protease Inhibitors
7.5. Reverse Transcriptase Inhibitors
- 7.6.1. Nonnucleoside RTIs
- 7.6.2. Nucleoside RTIs
- 7.6.3. Nucleotide RTIs

8. Antiviral Therapeutics Market, by Distribution

8.1. Introduction
8.2. Hospital Pharmacy
8.3. Independent Pharmacy & Drug Store
8.4. Online Pharmacy

9. Americas Antiviral Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Antiviral Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Antiviral Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Agreement, Collaboration, & Partnership
  - 12.3.1.1. Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
- 12.3.2. New Product Launch & Enhancement
  - 12.3.2.1. Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
- 12.3.3. Award, Recognition, & Expansion
  - 12.3.3.1. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. AbbVie Inc.
- 13.1.3. Alkem Laboratories Limited
- 13.1.4. AstraZeneca PLC
- 13.1.5. Atea Pharmaceuticals, Inc.
- 13.1.6. Aurobindo Pharma Limited
- 13.1.7. Bristol-Myers Squibb Company
- 13.1.8. Cipla Ltd.
- 13.1.9. Cocrystal Pharma, Inc.
- 13.1.10. Daiichi Sankyo Company, Ltd.
- 13.1.11. Dr. Reddy's Laboratories Ltd.
- 13.1.12. Eli Lilly and Company
- 13.1.13. F. Hoffmann-La Roche Ltd
- 13.1.14. Gilead Sciences, Inc.
- 13.1.15. GlaxoSmithKline PLC
- 13.1.16. Hetero Labs Limited
- 13.1.17. Johnson & Johnson Services Inc.
- 13.1.18. Merck & Co., Inc.
- 13.1.19. Novartis AG
- 13.1.20. Pfizer Inc.
- 13.1.21. Sanofi S.A.
- 13.1.22. Sun Pharmaceutical Industries Limited
- 13.1.23. Syngene International Limited
- 13.1.24. Takeda Pharmaceutical Company Limited
- 13.1.25. Themis Medicare Ltd.
- 13.1.26. Venatorx Pharmaceuticals, Inc.
- 13.1.27. Viatris Inc.
- 13.1.28. Zydus Lifesciences Limited
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing